TY - JOUR
T1 - Negligible impact of mass screening and treatment on mesoendemic malaria transmission at west timor in eastern Indonesia
T2 - A cluster-randomized trial
AU - Sutanto, Inge
AU - Kosasih, Ayleen
AU - Elyazar, Iqbal R.F.
AU - Simanjuntak, Deddy R.
AU - Larasati, Tri A.
AU - Dahlan, M. Sopiyudin
AU - Wahid, Isra
AU - Mueller, Ivo
AU - Koepfli, Cristian
AU - Kusriastuti, Rita
AU - Surya, Asik
AU - Laihad, Ferdinand J.
AU - Hawley, William A.
AU - Collins, Frank H.
AU - Baird, J. Kevin
AU - Lobo, Neil F.
N1 - Publisher Copyright:
© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America.
PY - 2018/10/15
Y1 - 2018/10/15
N2 - Background Mass screening and treatment (MST) aims to reduce malaria risk in communities by identifying and treating infected persons without regard to illness. Methods A cluster-randomized trial evaluated malaria incidence with and without MST. Clusters were randomized to 3, 2, or no MST interventions: MST3, 6 clusters (156 households/670 individuals); MST2, 5 clusters (89 households/423 individuals); and MST0, 5 clusters (174 households/777 individuals). All clusters completed the study with 14 residents withdrawing. In a cohort of 324 schoolchildren (MST3, n = 124; MST2, n = 57; MST0, n = 143) negative by microscopy at enrollment, we evaluated the incidence density of malaria during 3 months of MST and 3 months following. The MST intervention involved community-wide expert malaria microscopic screening and standard therapy with dihydroartemisinin-piperaquine and primaquine for glucose-6 phosphate dehydrogenase-normal subjects. All blood examinations included polymerase chain reaction assays, which did not guide on-site treatment. Results The risk ratios for incidence density of microscopically patent malaria in MST3 or MST2 relative to that in MST0 clusters were 1.00 (95% confidence interval [CI],.53-1.91) and 1.22 (95% CI,.42-3.55), respectively. Similar results were obtained with molecular analysis and species-specific (P. falciparum and P. vivax) infections. Microscopically subpatent, untreated infections accounted for 72% of those infected. Conclusions Two or 3 rounds of MST within 3 months did not impact the force of anopheline mosquito-borne infection in these communities. The high rate of untreated microscopically subpatent infections likely explains the observed poor impact. Clinical Trials Registration NCT01878357.
AB - Background Mass screening and treatment (MST) aims to reduce malaria risk in communities by identifying and treating infected persons without regard to illness. Methods A cluster-randomized trial evaluated malaria incidence with and without MST. Clusters were randomized to 3, 2, or no MST interventions: MST3, 6 clusters (156 households/670 individuals); MST2, 5 clusters (89 households/423 individuals); and MST0, 5 clusters (174 households/777 individuals). All clusters completed the study with 14 residents withdrawing. In a cohort of 324 schoolchildren (MST3, n = 124; MST2, n = 57; MST0, n = 143) negative by microscopy at enrollment, we evaluated the incidence density of malaria during 3 months of MST and 3 months following. The MST intervention involved community-wide expert malaria microscopic screening and standard therapy with dihydroartemisinin-piperaquine and primaquine for glucose-6 phosphate dehydrogenase-normal subjects. All blood examinations included polymerase chain reaction assays, which did not guide on-site treatment. Results The risk ratios for incidence density of microscopically patent malaria in MST3 or MST2 relative to that in MST0 clusters were 1.00 (95% confidence interval [CI],.53-1.91) and 1.22 (95% CI,.42-3.55), respectively. Similar results were obtained with molecular analysis and species-specific (P. falciparum and P. vivax) infections. Microscopically subpatent, untreated infections accounted for 72% of those infected. Conclusions Two or 3 rounds of MST within 3 months did not impact the force of anopheline mosquito-borne infection in these communities. The high rate of untreated microscopically subpatent infections likely explains the observed poor impact. Clinical Trials Registration NCT01878357.
KW - Indonesia
KW - cluster-randomized trial
KW - malaria control
KW - mass screening and treatment
UR - http://www.scopus.com/inward/record.url?scp=85051646932&partnerID=8YFLogxK
U2 - 10.1093/cid/ciy231
DO - 10.1093/cid/ciy231
M3 - Article
C2 - 29579195
AN - SCOPUS:85051646932
SN - 1058-4838
VL - 67
SP - 1364
EP - 1372
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 9
ER -